Robust antibody responses in 70-80-year-olds 3 weeks after the first or second doses of Pfizer/BioNTech COVID-19 vaccine, United Kingdom, January to February 2021.

More search options...

Subbarao, S; Warrener, LA; Hoschler, K; Perry, KR; Shute, J; Whitaker, H; O'Brien, M; Baawuah, F; Moss, P; Parry, H; et al. Subbarao, S; Warrener, LA; Hoschler, K; Perry, KR; Shute, J; Whitaker, H; O'Brien, M; Baawuah, F; Moss, P; Parry, H; Ladhani, SN; Ramsay, ME; Brown, KE; Amirthalingam, G (2021) Robust antibody responses in 70-80-year-olds 3 weeks after the first or second doses of Pfizer/BioNTech COVID-19 vaccine, United Kingdom, January to February 2021. Euro Surveill, 26 (12). ISSN 1560-7917 https://doi.org/10.2807/1560-7917.ES.2021.26.12.2100329
SGUL Authors: Ladhani, Shamez Nizarali

Preview

PDF Published Version
Available under License Creative Commons Attribution.
Download (224kB) | Preview

Abstract

Sera were collected from 185 adults aged ≥ 70 years in London to evaluate the immune response to COVID-19 vaccines. A single dose of Pfizer/BioNtech vaccine resulted in > 94% seropositivity after 3 weeks in naïve individuals using the Roche Spike antibody assay, while two doses produced very high spike antibody levels, significantly higher than convalescent sera from mild-to-moderate PCR-confirmed adult cases. Our findings support the United Kingdom's approach of prioritising the first dose and delaying the second dose of COVID-19 vaccine.

Item Type:

Article

Additional Information:

This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence and indicate if changes were made. Any supplementary material referenced in the article can be found in the online version. This article is copyright of the authors or their affiliated institutions, 2021.

Keywords: